Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer

Siobhan Sutcliffe, Edward Giovannucci, John F. Alderete, Te Hung Chang, Charlotte A Gaydos, Jonathan Mark Zenilman, Angelo Michael Demarzo, Walter C. Willett, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993-1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was assessed by a recombinant Trichomonas vaginalis α-actinin IgG ELISA. Results: Thirteen percent of cases and 9% of controls were seropositive for trichomonosis (adjusted odds ratio, 1.43; 95% confidence interval, 1.00-2.03). This association persisted after additional adjustment for such factors as a history of other STIs, and was strongest among men who used aspirin infrequently over the course of their lives (odds ratio, 2.05; 95% confidence interval, 1.05-4.02, P interaction = 0.11). Conclusions: Serologic evidence of a history of trichomonosis was positively associated with incident prostate cancer in this large, nested case-control study of male health professionals. As this study is the first, to our knowledge, to investigate associations between T. vaginalis serology and prostate cancer, additional studies are necessary before conclusions can be made.

Original languageEnglish (US)
Pages (from-to)939-945
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Trichomonas vaginalis
Prostatic Neoplasms
Sexually Transmitted Diseases
Antibodies
Case-Control Studies
Prostate
Odds Ratio
Confidence Intervals
Actinin
Gonorrhea
Health
Serology
Syphilis
Prostate-Specific Antigen
Aspirin
Carcinogenesis
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Infection

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. / Sutcliffe, Siobhan; Giovannucci, Edward; Alderete, John F.; Chang, Te Hung; Gaydos, Charlotte A; Zenilman, Jonathan Mark; Demarzo, Angelo Michael; Willett, Walter C.; Platz, Elizabeth A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 5, 05.2006, p. 939-945.

Research output: Contribution to journalArticle

@article{510dff07a9b3468895eaf0d06eac78f3,
title = "Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer",
abstract = "Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993-1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was assessed by a recombinant Trichomonas vaginalis α-actinin IgG ELISA. Results: Thirteen percent of cases and 9{\%} of controls were seropositive for trichomonosis (adjusted odds ratio, 1.43; 95{\%} confidence interval, 1.00-2.03). This association persisted after additional adjustment for such factors as a history of other STIs, and was strongest among men who used aspirin infrequently over the course of their lives (odds ratio, 2.05; 95{\%} confidence interval, 1.05-4.02, P interaction = 0.11). Conclusions: Serologic evidence of a history of trichomonosis was positively associated with incident prostate cancer in this large, nested case-control study of male health professionals. As this study is the first, to our knowledge, to investigate associations between T. vaginalis serology and prostate cancer, additional studies are necessary before conclusions can be made.",
author = "Siobhan Sutcliffe and Edward Giovannucci and Alderete, {John F.} and Chang, {Te Hung} and Gaydos, {Charlotte A} and Zenilman, {Jonathan Mark} and Demarzo, {Angelo Michael} and Willett, {Walter C.} and Platz, {Elizabeth A}",
year = "2006",
month = "5",
doi = "10.1158/1055-9965.EPI-05-0781",
language = "English (US)",
volume = "15",
pages = "939--945",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer

AU - Sutcliffe, Siobhan

AU - Giovannucci, Edward

AU - Alderete, John F.

AU - Chang, Te Hung

AU - Gaydos, Charlotte A

AU - Zenilman, Jonathan Mark

AU - Demarzo, Angelo Michael

AU - Willett, Walter C.

AU - Platz, Elizabeth A

PY - 2006/5

Y1 - 2006/5

N2 - Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993-1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was assessed by a recombinant Trichomonas vaginalis α-actinin IgG ELISA. Results: Thirteen percent of cases and 9% of controls were seropositive for trichomonosis (adjusted odds ratio, 1.43; 95% confidence interval, 1.00-2.03). This association persisted after additional adjustment for such factors as a history of other STIs, and was strongest among men who used aspirin infrequently over the course of their lives (odds ratio, 2.05; 95% confidence interval, 1.05-4.02, P interaction = 0.11). Conclusions: Serologic evidence of a history of trichomonosis was positively associated with incident prostate cancer in this large, nested case-control study of male health professionals. As this study is the first, to our knowledge, to investigate associations between T. vaginalis serology and prostate cancer, additional studies are necessary before conclusions can be made.

AB - Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993-1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was assessed by a recombinant Trichomonas vaginalis α-actinin IgG ELISA. Results: Thirteen percent of cases and 9% of controls were seropositive for trichomonosis (adjusted odds ratio, 1.43; 95% confidence interval, 1.00-2.03). This association persisted after additional adjustment for such factors as a history of other STIs, and was strongest among men who used aspirin infrequently over the course of their lives (odds ratio, 2.05; 95% confidence interval, 1.05-4.02, P interaction = 0.11). Conclusions: Serologic evidence of a history of trichomonosis was positively associated with incident prostate cancer in this large, nested case-control study of male health professionals. As this study is the first, to our knowledge, to investigate associations between T. vaginalis serology and prostate cancer, additional studies are necessary before conclusions can be made.

UR - http://www.scopus.com/inward/record.url?scp=33744750202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744750202&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0781

DO - 10.1158/1055-9965.EPI-05-0781

M3 - Article

VL - 15

SP - 939

EP - 945

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -